Our objective was to test the hypothesis that structure-based identified or designed compounds exhibiting neuroprotective, antioxidant, and anti-inflammatory properties in vitro will mitigate early seizures and neuropathology after traumatic brain injury (TBI) in vivo. The neuroprotective and anti-inflammatory effects of 11 compounds identified by computer-assisted approximations were tested in vitro in neuronal microglial co-cultures. Among these, compound FBA exhibited the best neuroprotective (MAP-2, microtubule-associated-protein 2, a neuronal damage biomarker), antioxidative (nitrite production), and anti-inflammatory effects in vitro (all p < 0.01). Consequently, its neuroprotective and antiseizure effects were assessed in vivo in adult male Sprague-Dawley rats exposed to severe lateral fluid-percussion-induced TBI. Rats under continuous video-electroencephalogram monitoring received prophylactic treatment with an intraperitoneal (i.p.) injection of FBA (FBApro, 30 mg/kg) or vehicle (VEH, 48% PEG in 0.9% saline, 3 mL/kg) at 2 and 24 h post-TBI. Rats that developed status epilepticus received 1–2 additional on-demand FBA doses (FBApro+, 100 mg/kg, i.p.) to stop epileptiform activity. FBApro treatment reduced the cortical lesion area (18.9 ± 4.1 mm2, n = 7) compared with VEH treatment (24.8 ± 5.7 mm2, n = 10, p < 0.05). FBApro treatment also showed a favorable effect on the white matter by reducing plasma levels of pNF-H, a biomarker of axonal injury, compared with VEH treatment (Cohen’s delta 0.657). Both FBApro (368 ± 407 s) and FBApro+ (256 ± 327 s) treatments reduced the average cumulative seizure duration compared with VEH (896 ± 703 s, both p < 0.05). The FBApro+ treatment regimen also reduced the mean relative theta and alpha power and increased the mean relative gamma power in the electroencephalogram (p < 0.05). Our data identified FBA as a novel structure-based discovered compound with promising favorable effects on structural and functional recovery after TBI.
Get full access to this article
View all access options for this article.
References
1.
DewanMC, RattaniA, GuptaS, et al.Estimating the global incidence of traumatic brain injury. J Neurosurg, 2019; 130(4):1080–1097; doi: 10.3171/2017.10.JNS17352
2.
MaasAIR, MenonDK, ManleyGT, et al.; InTBIR Participants and Investigators. Traumatic brain injury: Progress and challenges in prevention, clinical care, and research. Lancet Neurol, 2022; 21(11):1004–1060; doi: 10.1016/S1474-4422(22)00309-X
VellaMA, CrandallML, PatelMB. Acute management of traumatic brain injury. Surg Clin North Am, 2017; 97(5):1015–1030; doi: 10.1016/j.suc.2017.06.003
5.
JarrahiA, BraunM, AhluwaliaM, et al.Revisiting traumatic brain injury: From molecular mechanisms to therapeutic interventions. Biomedicines, 2020; 8(10):1–42; doi: 10.3390/biomedicines8100389
6.
PitkänenA, KharatishviliI, KarhunenH, et al.Epileptogenesis in experimental models. Epilepsia, 2007; 48(Suppl. 2):13–20; doi: 10.1111/j.1528-1167.2007.01063.x
7.
PitkänenA, KemppainenS, Ndode-EkaneXE, et al.Posttraumatic epilepsy—disease or comorbidity? Epilepsy Behav, 2014; 38:19–24; doi: 10.1016/j.yebeh.2014.01.013
8.
LaingJ, GabbeB, ChenZ, et al.Risk factors and prognosis of early posttraumatic seizures in moderate to severe traumatic brain injury. JAMA Neurol, 2022; 79(4):334–341; doi: 10.1001/jamaneurol.2021.5420
9.
VespaPM, NuwerMR, NenovV, et al.Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg, 1999; 91(5):750–760; doi: 10.3171/jns.1999.91.5.0750
10.
VespaPM, MillerC, McArthurD, et al.Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med, 2007; 35(12):2830–2836; doi: 10.1097/01.CCM.0000295667.66853.BC
11.
VespaPM, McArthurDL, XuY, et al.Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy. Neurology, 2010; 75(9):792–798; doi: 10.1212/WNL.0b013e3181f07334
12.
RitterAC, WagnerAK, FabioA, et al.Incidence and risk factors of posttraumatic seizures following traumatic brain injury: A traumatic brain injury model systems study. Epilepsia, 2016; 57(12):1968–1977; doi: 10.1111/epi.13582
13.
AnnegersJF, GrabowJD, GrooverRV, et al.Seizures after head trauma. Neurology, 1980; 30(7 Pt 1):683–689; doi: 10.1212/WNL.30.7.683
14.
AndradeP, Banuelos-CabreraI, LapinlampiN, et al.Acute Non-Convulsive status epilepticus after experimental traumatic brain injury in rats. J Neurotrauma, 2019; 36(11):1890–1907; doi: 10.1089/neu.2018.6107
15.
AnnegersJF, HauserWA, CoanSP, et al.A population-based study of seizures after traumatic brain injuries. N Engl J Med, 1998; 338(1):20–24; doi: 10.1056/NEJM199801013380104
16.
EnglanderJ, BushnikT, DuongTT, et al.Analyzing risk factors for late posttraumatic seizures: A prospective, multicenter investigation. Arch Phys Med Rehabil, 2003; 84(3):365–373; doi: 10.1053/apmr.2003.50022
17.
SchoutenJW. Neuroprotection in traumatic brain injury: A complex struggle against the biology of nature. Curr Opin Crit Care, 2007; 13(2):134–142; doi: 10.1097/MCC.0b013e3280895d5c
18.
DullaCG, PitkänenA. Novel approaches to prevent epileptogenesis after traumatic brain injury. Neurotherapeutics, 2021; 18(3):1582–1601; doi: 10.1007/s13311-021-01119-1
TaleviA. Computer-Aided drug discovery and design: Recent advances and future prospects. Methods Molecular Biol Humana Press Inc, 2024:1–20; doi: 10.1007/978-1-0716-3441-7_1
21.
DjikicT, MartíY, SpyrakisF, et al.Human dopamine transporter: The first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities. J Biomol Struct Dyn, 2019; 37(2):291–306; doi: 10.1080/07391102.2018.1426044
22.
ChandraS, WangZ, TaoX, et al.Computer-aided discovery of a new nav1.7 inhibitor for treatment of pain and itch. Anesthesiology, 2020; 133(3):611–627; doi: 10.1097/ALN.0000000000003427
23.
KaldorSW, KalishVJ, DaviesJF, et al.Viracept (Nelfinavir Mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem, 1997; 40(24):3979–3985; doi: 10.1021/jm9704098
LipponenA, NatunenT, HujoM, et al.In vitro and in vivo pipeline for validation of disease-modifying effects of systems biology-derived network treatments for traumatic brain injury—lessons learned. Int J Mol Sci, 2019; 20(21); doi: 10.3390/ijms20215395
26.
KajevuN, LipponenA, AndradeP, et al.Treatment of status epilepticus after traumatic brain injury using an antiseizure drug combined with a tissue recovery enhancer revealed by systems biology. Int J Mol Sci, 2023; 24(18); doi: 10.3390/ijms241814049
27.
SabatierLL, PalestroPH, EnriqueAV, et al.Design, synthesis and biological evaluation of N-substituted α-hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity. J Enzyme Inhib Med Chem, 2019; 34(1):1465–1473; doi: 10.1080/14756366.2019.1651722
28.
Ekolle Ndode-EkaneX, KharatishviliI, PitkänenA. Unfolded maps for quantitative analysis of cortical lesion location and extent after traumatic brain injury. J Neurotrauma, 2017; 34(2):459–474; doi: 10.1089/neu.2016.4404
29.
BooneDR, WeiszHA, WilleyHE, et al.Traumatic brain injury induces long-lasting changes in immune and regenerative signaling. PLoS One, 2019; 14(4):e0214741; doi: 10.1371/journal.pone.0214741
30.
SugimotoH, OguraH, AraiY, et al.REVIEW-New drug and recent technique-research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol, 2002.
31.
AkasofuS, KimuraM, KosasaT, et al.Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem Biol Interact, 2008; 175(1–3):222–226; doi: 10.1016/j.cbi.2008.04.045
32.
KimJ, LeeHJ, ParkSK, et al.Donepezil regulates LPS and aβ-stimulated neuroinflammation through MAPK/NLRP3 inflammasome/STAT3 signaling. Int J Mol Sci, 2021; 22(19); doi: 10.3390/ijms221910637
33.
WongJC, ThelinJT, EscaygA. Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome. Ann Clin Transl Neurol, 2019; 6(8):1566–1571; doi: 10.1002/acn3.50848
34.
ShimojoM, TakasugiK, YamamotoI, et al.Neuroprotective action of a novel compound-M50463-in primary cultured neurons 1. Brain Res, 1999; 815(1):131–139
35.
KamisliS, BasaranC, BatciogluK, et al.Neuroprotective effects of the new Na channel blocker rs100642 in global ischemic brain injury. Arch Med Sci, 2019; 15(2):467–474; doi: 10.5114/aoms.2017.72550
ImmonenRJ, KharatishviliI, NiskanenJP, et al.Distinct MRI pattern in lesional and perilesional area after traumatic brain injury in rat - 11 months follow-up. Exp Neurol, 2009; 215(1):29–40; doi: 10.1016/j.expneurol.2008.09.009
38.
HomsiS, PiaggioT, CrociN, et al.Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: A Twelve-Week follow-up study. J Neurotrauma, 2010; 27(5):911–921; doi: 10.1089/neu.2009.1223
39.
YangL, LiuZ, RenH, et al.DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury. Metab Brain Dis, 2017; 32(5):1395–1402; doi: 10.1007/s11011-017-9991-6
40.
WilliamsAM, BhattiUF, BrownJF, et al.Early Single-Dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg, 2020; 88(2):207–218; doi: 10.1097/TA.0000000000002563
41.
GultekinR, HuangS, ClavisiO, et al.Pharmacological interventions in traumatic brain injury: Can we rely on systematic reviews for evidence? Injury, 2016; 47(3):516–524; doi: 10.1016/j.injury.2015.10.011
42.
MountneyA, ShearDA, PotterB, et al.Ethosuximide and phenytoin dose-dependently attenuate acute nonconvulsive seizures after traumatic brain injury in rats. J Neurotrauma, 2013; 30(23):1973–1982; doi: 10.1089/neu.2013.3001
43.
SchierhoutG, RobertsI. Prophylactic antiepileptic agents after head injury: A systematic review. J Neurol Neurosurg Psychiatry, 1998; 64(1):108–112; doi: 10.1136/jnnp.64.1.108
44.
PitkänenA. Therapeutic approaches to epileptogenesis - Hope on the Horizon. In: Epilepsia, 2010; 51(Suppl 3):2–17; doi: 10.1111/j.1528-1167.2010.02602.x
45.
HernandezTD. Preventing post-traumatic epilepsy after brain injury: Weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmacol Sci, 1997; 18(2):59–62; doi: 10.1016/S0165-6147(97)89801-X
46.
CoelhoLMG, BlackerD, HsuJ, et al.Association of early seizure prophylaxis with posttraumatic seizures and mortality. Neur Clin Pract, 2023; 13(3); doi: 10.1212/cpj.0000000000200145
47.
TrinkaE, LeitingerM. Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn), 2022; 28(2):559–602
48.
MigdadyI, RosenthalES, CockHR. Management of status epilepticus: A narrative review. Anaesthesia, 2022; 77(S1):78–91; doi: 10.1111/anae.15606
49.
SohalVS, ZhangF, YizharO, et al.Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature, 2009; 459(7247):698–702; doi: 10.1038/nature07991
50.
GuerrieroRM, GizaCC, RotenbergA. Glutamate and GABA imbalance following traumatic brain injury. Curr Neurol Neurosci Rep, 2015; 15(5):27; doi: 10.1007/s11910-015-0545-1
51.
FergusonB, GlickC, HuguenardJR. Prefrontal PV interneurons facilitate attention and are linked to attentional dysfunction in a mouse model of absence epilepsy. Elife, 2023; 12; doi: 10.7554/eLife.78349
52.
ÁlvarezXA, SampedroC, FigueroaJ, et al.Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm (Vienna), 2008; 115(5):683–692; doi: 10.1007/s00702-008-0024-9
53.
ChoKKA, HochR, LeeAT, et al.Gamma rhythms link prefrontal interneuron dysfunction with cognitive inflexibility in dlx5/6+/- mice. Neuron, 2015; 85(6):1332–1343; doi: 10.1016/j.neuron.2015.02.019
54.
PrichepLS. Quantitative EEG and Electromagnetic Brain Imaging in aging and in the Evolution of Dementia. Annals of the New York Academy of Sciences Blackwell Publishing Inc.; 2007; pp. 156–167; doi: 10.1196/annals.1379.008
55.
CaoY, HanC, PengX, et al.Correlation between resting theta power and cognitive performance in patients with schizophrenia. Front Hum Neurosci, 2022; 16:853994; doi: 10.3389/fnhum.2022.853994
56.
NuwerMR, HovdaDA, SchraderLM, et al.Routine and quantitative EEG in mild traumatic brain injury. Clin Neurophysiol, 2005; 116(9):2001–2025; doi: 10.1016/j.clinph.2005.05.008
57.
Valdés-HernándezPA, Ojeda-GonzálezA, Martínez-MontesE, et al.White matter architecture rather than cortical surface area correlates with the EEG alpha rhythm. Neuroimage, 2010; 49(3):2328–2339; doi: 10.1016/j.neuroimage.2009.10.030
58.
KlimeschW. EEG alpha and theta oscillations reflect cognitive and memory performance: A review and analysis. Brain Res Brain Res Rev, 1999; 29(2–3):169–195; doi: 10.1016/S0165-0173(98)00056-3
59.
ZhaoX, ChenX, DuanW, et al.Impaired alpha rhythm in bad sleeper during nap: A high-density electroencephalogram study. J Sleep Res, 2022; 31(1):e13419; doi: 10.1111/jsr.13419
60.
MaierLE, LampelHP, BhutaniT, et al.Hand dermatitis: A focus on allergic contact dermatitis to biocides. Dermatol Clin, 2009; 27(3):251–264; doi: 10.1016/j.det.2009.05.007
61.
JulianoC, MagriniGA. Cosmetic ingredients as emerging pollutants of environmental and health concern. A mini-review. Cosmetics, 2017; 4(2):11; doi: 10.3390/cosmetics4020011
TaleviA, EnriqueAV, Bruno-BlanchLE. Anticonvulsant activity of artificial sweeteners: A structural link between sweet-taste receptor T1R3 and brain glutamate receptors. Bioorg Med Chem Lett, 2012; 22(12):4072–4074; doi: 10.1016/j.bmcl.2012.04.076
64.
Van EykAD. The effect of five artificial sweeteners on Caco-2, HT-29 and HEK-293 cells. Drug Chem Toxicol, 2015; 38(3):318–327; doi: 10.3109/01480545.2014.966381
65.
Pisera-FusterA, OteroS, TaleviA, et al.Anticonvulsant effect of sodium cyclamate and propylparaben on pentylenetetrazol-induced seizures in zebrafish. Synapse, 2017; 71(4); doi: 10.1002/syn.21961
66.
KimuraM, HayashidaK, EisenachJC, et al.Relief of hypersensitivity after nerve injury from systemic donepezil involves spinal cholinergic and γ-Aminobutyric acid mechanisms. Anesthesiology, 2013; 118(1):173–180; doi: 10.1097/ALN.0b013e318277a81c
67.
CouyoupetrouM, TaleviA, MeR, et al.Latin American congress on epilepsy—Abstracts. Epileptic Disorders, 2014; 16(NS3):1–54; doi: 10.1684/epd.2014.0694
68.
VillalbaML, EnriqueAV, HiggsJ, et al.Novel sulfamides and sulfamates derived from amino esters: Synthetic studies and anticonvulsant activity. Eur J Pharmacol, 2016; 774:55–63; doi: 10.1016/j.ejphar.2016.02.001
69.
VillalbaML, PalestroP, CerusoM, et al.Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action. Bioorg Med Chem, 2016; 24(4):894–901; doi: 10.1016/j.bmc.2016.01.012
70.
BousquetJ, DemolyP, HumbertM. Montelukast in guidelines and beyond. Adv Ther, 2009; 26(6):575–587; doi: 10.1007/s12325-009-0038-1
71.
Al SaadiMM, MeoSA, MustafaA, et al.Effects of montelukast on free radical production in whole blood and isolated human Polymorphonuclear Neutrophils (PMNs) in asthmatic children. Saudi Pharm J, 2011; 19(4):215–220; doi: 10.1016/j.jsps.2011.06.002
72.
CevikB, SolmazV, AksoyD, et al.Montelukast inhibits pentylenetetrazol-induced seizures in rats. Med Sci Monit, 2015; 21:869–874; doi: 10.1265/9/MSM.892932
73.
LlanosMA, EnriqueN, SbaragliniML, et al.Structure-Based virtual screening identifies novobiocin, montelukast, and cinnarizine as TRPV1 modulators with anticonvulsant activity in vivo. J Chem Inf Model, 2022; 62(12):3008–3022; doi: 10.1021/acs.jcim.2c00312
74.
Rodríguez-CerratoV, del PradoG, HuelvesL, et al.Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by β-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents, 2010; 35(6):544–549; doi: 10.1016/j.ijantimicag.2010.02.007
75.
EnriqueAV, Di IanniME, GoicoecheaS, et al.New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice. Epilepsy Behav, 2021; 121(Pt B):106451; doi: 10.1016/j.yebeh.2019.106451
76.
AhmadM, Abu-TaweelGM, AboshaiqahAE, et al.The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus. Oxid Med Cell Longev, 2014; 2014:630509; doi: 10.1155/2014/630509
77.
AhmadM, WadaanM, Pharm SciPJ, et al.Ameliorating effects of proglumide on neurobehavioral and biochemical deficits in animal model of status epilepticus. Pak J Pharm Sci, 2014; 27(6):1945–1951
78.
TrinkaE, CockH, HesdorfferD, et al.A definition and classification of status epilepticus—report of the ILAE task force on classification of status epilepticus. Epilepsia, 2015; 56(10):1515–1523; doi: 10.1111/epi.13121
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
